Dual therapy with infliximab and IVIG in children with multi-system inflammatory syndrome
1. In a single center retrospective cohort study of children with multi-system inflammatory syndrome (MIS-C), children treated with IVIG and...
Rheumatology
Use of sodium-glucose transport protein 2 inhibitors associated with lowered incidence of gout in patients with type 2 diabetes
1. The use of sodium-glucose transport protein 2 inhibitors in patients with type 2 diabetes was associated with a lowered...
Belimumab after rituximab reduces risk for severe flare in systemic lupus erythematosus
1. Belimumab combined with rituximab was shown to significantly reduce IgG anti-dsDNA antibody levels in patients with systemic lupus erythematosus....
Platelet-rich plasma injections did not significantly improve ankle symptoms compared to placebo in patients with ankle osteoarthritis
1. This trial included 100 patients and took place over a 26-week period, ultimately concluding that platelet-rich plasma (PRP) injections...
Study finds most patients with multisystem inflammatory syndrome in children (MIS-C) fully recover
1. In this single-center study of children hospitalized with MIS-C, most had complete recovery of cardiac function. 2. While most...
Platelet-rich plasma injection does not significantly improve chronic midportion Achilles tendinopathy outcomes
1. The clinical outcome of chronic midportion Achilles tendinopathy, measured via the Victorian Institute of Sport Assessment-Achilles score, did not...
Filgotinib effectively induces and maintains clinical remission in patients with ulcerative colitis
1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the...
Rituximab increases sustained complete remission in patients with pemphigus vulgaris
1. A higher sustained complete remission rate was shown with rituximab treatment compared to mycophenolate mofetil in patients with pemphigus...
Ziltivekimab antagonism of IL-6 reduces inflammation and thrombosis in patients with atherosclerotic risk factors
1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner. 2. Thrombotic...
Voclosporin shows clinical promise for treatment of active lupus nephritis
1. A significantly greater proportion of patients in the voclosporin group achieved complete renal responses after 52 weeks compared to...